Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Shares Issued (2021 - 2025)

Historic Shares Issued for Rani Therapeutics Holdings (RANI) over the last 5 years, with Q3 2025 value amounting to -$68000.0.

  • Rani Therapeutics Holdings' Shares Issued fell 10076.55% to -$68000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year decrease of 5697.56%. This contributed to the annual value of $51000.0 for FY2024, which is 2750.0% up from last year.
  • Latest data reveals that Rani Therapeutics Holdings reported Shares Issued of -$68000.0 as of Q3 2025, which was down 10076.55% from $3.9 million recorded in Q2 2025.
  • Rani Therapeutics Holdings' Shares Issued's 5-year high stood at $8.9 million during Q3 2024, with a 5-year trough of -$570000.0 in Q4 2021.
  • Moreover, its 5-year median value for Shares Issued was $13000.0 (2021), whereas its average is $808400.0.
  • In the last 5 years, Rani Therapeutics Holdings' Shares Issued crashed by 36530.61% in 2023 and then skyrocketed by 1128846.15% in 2024.
  • Quarter analysis of 5 years shows Rani Therapeutics Holdings' Shares Issued stood at -$570000.0 in 2021, then skyrocketed by 74.04% to -$148000.0 in 2022, then soared by 72.97% to -$40000.0 in 2023, then dropped by 20.0% to -$48000.0 in 2024, then tumbled by 41.67% to -$68000.0 in 2025.
  • Its Shares Issued was -$68000.0 in Q3 2025, compared to $3.9 million in Q2 2025 and $42000.0 in Q1 2025.